Research and Markets: Lung Cancer Vaccines: 2011 Pipeline, Strategies and Clinical

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2df637/lung_cancer_vaccin) has announced the addition of the "Lung Cancer Vaccines: Pipeline, Strategies and Clinical" report to their offering.

“Lung Cancer Vaccines: Pipeline, Strategies and Clinical”

This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n=5) pipeline vaccines and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n=37) pipeline vaccines and companies
• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
• Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved
• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment of lung cancer
• Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer
• Commercial partnerships and collaborations on pipeline therapeutic vaccines
• Drug combination strategies in the evaluation of therapeutic vaccines for the targeting of lung cancer
• A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment of lung cancer
• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment of lung cancer
• Competitive and market-related information

Key Topics Covered:

Chapter 1 Background

Chapter 2 Approved and Late-Stage Vaccines

Chapter 3 Early-Stage Vaccines

Chapter 4 Other Candidate Therapies

Chapter 5 Discussion

For more information visit http://www.researchandmarkets.com/research/2df637/lung_cancer_vaccin